Additional file 1 of Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway

Additional file 1: Figure S1. The correlation between the expression level of plasma exosomal miR-361-3p and clinical factors in BC patients. (A) The box plot shows the relationship between the plasma exosomal miR-361-3p and the clinical factors of BC patients. Figure S2. Downregulation of miR-361-3p expression inhibits BC cell viability (A) qRT‒PCR was performed to detect the expression level of miR-361-3p in BC cells transfected with miR-361-3p inhibitor or miR-NC inhibitor. CellTiter-Glo assays (B), wound healing assays (C) and Transwell assays (D) were performed to test the effect of miR-361-3p knockdown on BC cell proliferation and metastasis. Scale bars, 100 μm. (E) Relative protein expression of ETV7 and BATF2 after transfecting with miR-361-3p inhibitor or miR-NC inhibitor. (*P < 0.05, **P < 0.01)